4/A: AVNS CFO Equity Grant Corrected in Amended SEC Filing

An amended SEC filing clarifies the equity awards granted to Avanos Medical's CFO, Scott Michael Galovan, correcting an error in stock option calculations.

Summary

• Avanos Medical, Inc. (AVNS) filed an amended Form 4/A to correct an error in the calculation of stock options granted to its SVP, Chief Financial Officer, Scott Michael Galovan.
• The original transaction date for the awards was March 13, 2026.
• Mr. Galovan was awarded 29,481 time-based restricted share units (TRSUs) under the Issuer's 2021 Long Term Incentive Plan, as amended.
• These TRSUs will vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029.
• Additionally, 70,115 employee stock options were awarded with an exercise price of $13.69.
• The stock options will vest 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029, and expire on March 13, 2036.
• Following these transactions, Mr. Galovan beneficially owns 139,824 shares of common stock and 96,697 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an error required correction, the underlying equity grant is a positive for executive alignment, and the prompt amendment demonstrates transparency.

Positives

• The grant of 29,481 time-based restricted share units (TRSUs) and 70,115 employee stock options aligns the CFO's incentives with long-term shareholder value.
• The company promptly corrected an administrative error in the filing, demonstrating transparency and adherence to regulatory requirements.

Negatives

• An initial error in the calculation of stock options required an amendment, indicating a minor administrative oversight.

Future Outlook

The vesting schedules for the TRSUs and stock options extend through March 2029, indicating a long-term incentive structure for the CFO. The stock options have an expiration date of March 13, 2036.

Management Comments

• The filing was signed by John Hurley, as attorney-in-fact for Scott M. Galovan.

Industry Context

StockSavvy.ai notes that equity grants to senior executives like the CFO are standard practice in the medical device industry, aligning management's interests with long-term company performance and shareholder returns. The use of both restricted stock units and stock options is a common approach to executive compensation, balancing retention with performance incentives.

Comparison to Industry Standards

• The structure of equity compensation, including both time-based restricted share units and employee stock options, is consistent with common practices observed in the broader healthcare and medical technology sectors. For example, companies like Medtronic (MDT) and Stryker (SYK) frequently utilize similar long-term incentive vehicles for their executive teams.
• The vesting schedule, typically over three years, is also a standard industry benchmark for executive retention and performance alignment, comparable to plans at companies such as Boston Scientific (BSX) or Abbott Laboratories (ABT).

Stakeholder Impact

• Shareholders: The equity awards align the CFO's interests with long-term shareholder value, potentially fostering sustained performance.
• Employees: The filing pertains to executive compensation and does not directly impact the broader employee base, though it reflects the company's incentive philosophy.

Next Steps

• The TRSUs will vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029.
• The employee stock options will vest 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029.

Key Dates

Recommendation

This Form 4/A filing is an administrative correction of an executive equity grant and does not contain information that would fundamentally alter the investment thesis for Avanos Medical. The grant itself is a standard executive compensation practice. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment position.

Keywords

AVANOS MEDICAL, AVNS, SEC Form 4/A, Equity Grant, Stock Options, Restricted Share Units, CFO Compensation, Executive Compensation, Insider Trading, Long-Term Incentive Plan